Free Republic

A large-scale study provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is just as effective as conventional radiotherapy for prostate cancer, without compromising safety. The shorter approach, known as isodose moderately hypofractionated radiotherapy (MHFRT), delivers slightly higher doses of radiation per session, allowing the total treatment duration to be over four to five weeks instead of seven to eight weeks. Patients who received this type of MHFRT had the same cancer control rates as those who received conventional radiotherapy. Additionally, the risk of long-term side effects affecting the bladder and intestines was no higher with MHFRT,...

Researchers are warning that men who regularly dodge prostate cancer screening appointments are 45% more likely to die from the disease. Prostate cancer is the most common cancer among men and the second-leading cause of cancer deaths, according to UC San Francisco (UCSF). But if screening programs are introduced on a national scale — particularly those that measure levels of prostate-specific antigen (PSA) in the blood — they could give men earlier access to treatment, experts say. They would thus have a better chance of being cured, according to reporting by news agency SWNS and others.

In a nutshell * A new urine test can detect aggressive prostate cancer without requiring an uncomfortable rectal exam, potentially allowing for at-home sample collection * In a study of 266 men, the test identified over 92% of aggressive cancers while potentially reducing unnecessary biopsies by up to 42% * The test looks for 18 specific genes linked to prostate cancer and provides a clear percentage score indicating the likelihood of finding significant cancer =================================================================================== ANN ARBOR, Mich. — Prostate cancer is the second leading cause of cancer for men living in the United States, according to the American Cancer...

Researchers now understand why taking an investigational white button mushroom supplement shows promise in slowing and even preventing prostate cancer from spreading among men who joined a phase 2 clinical trial studying "food as medicine." Looking at preclinical and preliminary human data, the scientists found that taking white button mushroom pills reduces a class of immune cells called myeloid-derived suppressor cells (MDSCs), which has been linked to cancer development and spread. "City of Hope researchers are investigating foods like white button mushroom, grape seed extract, pomegranate, blueberries and ripe purple berries called Jamun for their potential medicinal properties. We're finding...

A research team has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer. Small cell carcinomas can arise in various tissues—including the bladder, prostate, lung, ovaries and breast—and are known for their rapid progression, tendency to relapse after initial treatment and poor overall survival rates. The survival time for patients with advanced small cell bladder cancer is only about 7 to 13 months and only 7 to 9 months for patients with small cell/neuroendocrine prostate cancer. The early-stage study showed that using pembrolizumab...

Researchers have published a case report that signifies a potential breakthrough in the treatment of an aggressive type of prostate cancer. The report centers around a 60-year-old Air Force Veteran diagnosed with stage four metastatic prostate cancer and the positive outcomes of being treated with trastuzumab deruxtecan (T-DXd), an antibody drug conjugate. The patient did not respond to multiple lines of therapy and experienced persistent tumor progression. As a last resort, the researchers tested for HER2 by immunohistochemistry, which came back positive and the patient was treated off-label in February 2024 with T-DXd. The antibody drug conjugate, which is FDA...

Prostate cancer is a quiet killer. In most men, it's treatable. However, in some cases, it resists all known therapies and turns extremely deadly. A new discovery at Cold Spring Harbor Laboratory (CSHL) points to a potentially groundbreaking solution. CSHL Professor Lloyd Trotman's lab has found that the pro-oxidant supplement menadione slows prostate cancer progression in mice. The supplement is a precursor to vitamin K, commonly found in leafy greens. In 2001, the National Cancer Institute's SELECT trial sought to determine if an antioxidant vitamin E supplement could successfully treat or prevent prostate cancer. However, after just three years, participants...

A team tested the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer cell models in the laboratory. Prostate cancer may progress from benign hyperplasia (growth of the prostate) to localized prostate cancer, or to metastatic castration-resistant cancer, for which few drugs are available. María Loreta Libero recently studied the beneficial effects of a fermented black garlic extract on prostate cancer cells. Taking into account a previous experiment in mice in which the extract was found to have anti-inflammatory characteristics, and considering the important role...

For years, the treatment of early-stage prostate cancers that haven't spread beyond the organ has often included the removal of nearby lymph nodes in the pelvis. It's done as a precaution and as a means of "staging" the disease. Now, a major expert review on the topic suggests that, in many cases, men in this situation may be better off keeping their lymph nodes. Doing so may help them avoid harmful side effects, such as disabling lymphedema. But even more importantly, leaving the pelvic nodes intact might also boost the success of newer immune-based cancer drugs, the experts suspect. One...

Two reduced dose radiopharmaceutical therapy approaches for advanced stage metastatic castrate-resistant prostate cancer have been shown to be just as effective as the standard dose, according to research. Treatment with deescalated 225Ac-PSMA-617 or a cocktail therapy of 177Lu/225Ac-PSMA-617 resulted in similar median overall survival and prostate specific antigen (PSA) response rates as the standard 225Ac-PSMA-617 dose and was better-tolerated. The standard dose for 225Ac-PSMA targeted radiopharmaceutical alpha-therapy is 100 kBq per kilogram of body weight or an approximation of eight MBq. "Preliminary data has shown that reduced doses result in lower rates of dry mouth while still maintaining promising anti-tumor...

Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic castration-resistant prostate cancer patients, according to new research. Selected patients who received extended treatment—either continuously or following a treatment break—experienced a favorable median survival of 31.3 months from the first administration. Said Wolfgang P. Fendler, MD., "It may be beneficial to extend the use of 177Lu-PSMA, however, systematic data on safety and the antitumor effect of 177Lu-PSMA radiopharmaceutical therapy beyond six cycles is scarce." The multicenter retrospective analysis included 111 metastatic castration-resistant prostate cancer patients who received more than six cycles...

Adding a pre-ketone supplement—a component of a high-fat, low-carb ketogenic diet—to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer, researchers found. Prostate cancer is resistant to a type of immunotherapy called immune checkpoint blockade (ICB) therapy. ICB therapy paves the way for our body's fighter cells, T cells, to kill the cancer. Murphy divided the models into different groups: immunotherapy alone, ketogenic diet alone, a pre-ketone supplement alone, the ketogenic diet with the immunotherapy, the supplement with the immunotherapy, and the control. While the immunotherapy alone had almost no effect on the...

New urine-based test looks at 18 genes and was specifically developed to pick out those cancers that need immediate treatment over the slow-growing type. Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment. The test, called MyProstateScore2.0, or MPS2, looks at 18 different genes linked to high-grade prostate cancer. In multiple tests using urine and tissue samples from men with prostate cancer, it successfully identified...

The largest study to date investigating a single invitation to a PSA blood test to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial. After following up for 15 years, there was a small...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, research suggests A new meta-analysis suggests doctors and patients can avoid unnecessary prostate biopsies by combining MRI of the prostate findings with prostate-specific antigen (PSA) density. To doctors, clinically significant prostate cancer (csPCa) is prostate cancer that has a high chance of threatening a patient's life. MRI of the prostate can provide some of this information. Still, a biopsy is traditionally needed to determine how aggressive the cancer cells look. This study tested a new approach: combining MRI-based prostate imaging...

Lloyd Austin underwent an invasive surgical procedure called a prostatectomy for his prostate cancer. He was readmitted to the ICU ward of Walter Reed National Military Medical Center seven days later, on January 1st, due to complications caused by a severe infection. It appears he was septic. He concealed his inability to carry out his duties from Biden, Congress, the Pentagon, and his Deputy Secretary, Dr. Kathleen Hicks. On January 4th, finally becoming aware of Austin’s hospitalization, security adviser Jake Sullivan notified Hicks, who was on vacation in Puerto Rico. Even though Biden continued to back Austin, Austin was already...

An increase in annual cardiorespiratory fitness by 3% or more is linked to a 35% lower risk of developing, although not dying from, prostate cancer, suggests research. They wanted to find out if improvements in cardiorespiratory fitness over time might influence these risks, drawing on a national occupational health profile assessment database. The database collected information on physical activity, lifestyle, perceived health, measurement of body mass and height, and the results of at least two cardiorespiratory fitness tests, measured by peddling on a stationary cycle, for 57,652 men out of a total of 181,673. Annual cardiorespiratory fitness measurements were expressed...

U.S. Defense Secretary Lloyd Austin was recently diagnosed and is being treated for prostate cancer. He is one of the nearly 290,000 American men who will be diagnosed with the condition this year. Nearly all types of cancer have become less deadly over the last 30 years, with one notable exception: advanced-stage prostate cancer, according to a recent report from the American Cancer Society (ACS). “We have had more men diagnosed with more advanced prostate cancer over the last decade,” Dr. Sam S. Chang, the Chief Surgical Officer at the Vanderbilt Ingram Cancer Center, told The Epoch Times in an...

Joe Biden was not informed of the prostate cancer diagnosis of Secretary of Defense Lloyd Austin until today, National Security Council spokesman John Kirby told reporters at Tuesday’s White House press briefing. Kirby said Biden was told of Austin’s illness by White House Chief of Staff Jeff Zients in the morning. A press release earlier Tuesday by doctors treating Austin revealed his cancer diagnosis. ..... Snip..... Biden spoke by phone with Austin on Saturday, reported Politico’s Alex Ward, “Biden held a “cordial conversation” with Austin on Saturday night, per one of the U.S. officials. “The president has complete trust and...

Scientists wanted to investigate the anti-cancer properties of carnosine against cells derived from both primary and metastatic prostate cancer. Carnosine, which can be produced by the body and is also found in meat, has long been advocated for use as an antioxidant to facilitate healthy aging. There have been reports of carnosine being effective against the development of a number of different cancers but this is the first time it has been studied in relation to prostate cancer. The researchers found that carnosine stopped the cells from multiplying and at higher doses even killed cancer from both primary and metastatic...